Medtronic Is Leading Innovation in Diabetes Technology


Medtronic Is Leading Innovation in Diabetes Technology

by Bonnie Goldberg, MA, RD, CDE

Bonnie is a Registered Dietitian with a Masters Degree in Health Education from Columbia University. She specializes in diabetes care and has spent her career educating and empowering people with diabetes. She is proud to currently work for Medtronic.

At Medtronic, we’re proud to introduce two new members of the MiniMed family—the MiniMed® 670G sytem and the MiniMed® 630G system. On September 28, the FDA approved the world’s first hybrid closed loop insulin delivery system. This brand-new system automates basal insulin delivery based on the personalized needs of the user, maximizing the time glucose levels are within the target range.  It is designed to learn what an individual’s insulin needs are and to take action to minimize the time people with type 1 diabetes have both high and low glucose levels. The system also features the latest in continuous glucose monitoring (CGM) with the Guardian® Sensor 3, our newest and most advanced glucose sensor with enhanced accuracy and performance, a longer 7-day life.  It is also the first and only sensor approved by the FDA to control a hybrid closed loop system. 

The MiniMed 670G system will be commercially available spring of 2017 as Medtronic ensures market and manufacturing readiness, patient access, and appropriate employee, clinician, and patient training.

In the meantime, we also launched the brand-new MiniMed 630G system in August 2016. That’s right, the #1 most prescribed insulin pump system has been completely redesigned with a fresh new look, added capabilities, and a simplified user interface.

So, what’s new in the MiniMed 630G system?

Color Screen

The MiniMed 630G insulin pump has a bright, high-contrast color screen that adjusts automatically to suit in the light in your environment. It’s as easy to read in bright sunlight as it is in the middle of the night.


Are you tired of disconnecting from your pump every time you participate in water activities, like going out on a boat or to a waterpark? Not anymore. The new MiniMed 630G pump is waterproof in 12 feet of water for up to 24 hours at the time of manufacture.

Remote Bolusing

The MiniMed 630G system also exclusively uses the CONTOUR®NEXT LINK 2.4 blood glucose meter to provide highly accurate blood glucose testing. The meter automatically transmits blood glucose results to calculate boluses using the Bolus Wizard® calculator and to calibrate the continuous glucose monitor (CGM) sensor, which helps prevent manual entry errors. It also allows patients to discreetly give themselves a bolus of insulin remotely from the meter, providing added convenience to help patients manage their diabetes effectively.

Intuitive Navigation and More Customization

The MiniMed 630G system has simplified, user-friendly navigation that includes:

  • Home screen status bar that shows active insulin, blood glucose or sensor glucose readings, and bolus and basal options
  • Up to 8 customizable basal patterns that include settings for Work Day, Sick Day, and other variations from your everyday routine that could affect your basal needs
  • There are also 8 customizable temp basal patterns to accommodate times of high or low activity
  • Preset bolus options for when you know the exact amount of insulin you need for your meal, like if you eat the same breakfast every day
  • Optional airplane mode if you choose to discontinue communication between your pump and sensor while flying. Your CGM will still collect data for up to 10 hours.

Part of a Family

The MiniMed 670G system and the MiniMed 630G system join our family of diabetes management products, including our MiniMed® 530G system which we will continue to provide. The MiniMed 530G system is popular for its ability to be used with MiniMed Connect mobile accessory, which allows people with diabetes to discreetly view CGM data on their smartphones as well as remote monitoring for their care partners. So, we can now offer products that meet the different lifestyle needs of people with diabetes.

Finally, an insulin pump system that offers the greatest clinical benefit AND is customizable to fit your individual needs. Now, you can spend less time managing highs and lows and more time living the life you love!

Click here for more information and to check your eligibility for a FREE TRIAL of the MiniMed 630 system. In addition, purchasing a MiniMed 630G system NOW is your ticket to Priority Access for the MiniMed 670G system when it becomes available in the spring of 2017. Click here for more information on how your out-of-pocket cost for the world’s first hybrid closed loop insulin delivery system could go as low as $0**.

Important Safety Information

MiniMed® 530g and MiniMed® 630G system with SmartGuard™ technology

The MiniMed 530G and MiniMed 630G systems with SmartGuard technology are intended for the delivery of insulin and continuous glucose monitoring for the management of diabetes mellitus in persons 16 years of age or older who require insulin. Insulin infusion pumps and associated components of insulin infusion systems are limited to sale by or on the order of a physician and should only be used under the direction of a healthcare professional familiar with the risks of insulin pump therapy. Pump therapy is not recommended for people who are unwilling or unable to perform a minimum of four blood glucose tests per day. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Insulin pumps use rapid-acting insulin. If your insulin delivery is interrupted for any reason, you must be prepared to replace the missed insulin immediately. Replace the infusion set every 48–72 hours, or more frequently per your healthcare professional’s instructions. Insertion of a glucose sensor may cause bleeding or irritation at the insertion site. Consult a physician immediately if you experience significant pain or if you suspect that the site is infected. The information provided by CGM systems is intended to supplement, not replace, blood glucose information obtained using a blood glucose meter. A confirmatory fingerstick using a CONTOUR®NEXT LINK portfolio meter* is required prior to making adjustments to diabetes therapy. Always check the pump display when using a CONTOUR®NEXT LINK portfolio meter*, to ensure the glucose result shown agrees with the glucose results shown on the meter. Do not calibrate your CGM device or calculate a bolus using a result taken from an Alternative Site (palm) or a result from a control solution test. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode. Do not calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. The MiniMed 530G and MiniMed 630G systems are not intended to be used directly for preventing or treating hypoglycemia but to suspend insulin delivery when the user is unable to respond to the Suspend on low alarm and take measures to prevent or treat hypoglycemia themselves. Therapy to prevent or treat hypoglycemia should be administered according to the recommendations of the user’s healthcare provider. WARNING: The SmartGuard feature will cause the pump to temporarily suspend insulin delivery for two hours when the sensor glucose reaches a set threshold. Under some conditions of use the pump can suspend again, resulting in very limited insulin delivery. Prolonged suspension can increase the risk of serious hyperglycemia, ketosis, and ketoacidosis. Before using the SmartGuard feature, it is important to read the SmartGuard feature information in the User Guide and discuss proper use of the feature with your healthcare provider. See and the appropriate user guides for additional important details.

*The CONTOUR®NEXT LINK Meter is used with the MiniMed 530G system. The CONTOUR®NEXT LINK 2.4 Meter is used with the MiniMed 630G system.

Important Safety Information

MiniMed 670G system

The Medtronic MiniMed 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons, fourteen years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed 670G system includes SmartGuard technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitor sensor glucose values, and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values. The Medtronic MiniMed 670G system consists of the following devices: MiniMed 670G insulin pump, the Guardian Link (3) transmitter, the Guardian Sensor (3), One-press serter, and the CONTOUR®NEXT LINK 2.4 glucose meter. The system requires a prescription. The Guardian Sensor (3) glucose values are not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. All therapy adjustments should be based on measurements obtained using a home blood glucose monitor and not on values provided by the Guardian Sensor (3).  IMPORTANT: Medtronic  performed an evaluation of the 670G close loop system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements.  Therefore, this device should not be used in anyone under the age of 7 years old. This device should also not be used in patient who require less than a total daily insulin does of 8 units per day because the device requires a minimum of 8 units per day to operate safely. The MiniMed 670G system is not approved for use in pregnant women and patients with impaired kidney function. For complete warnings, precautions and contraindications, please consult the User Guide.

**Offer available until December 31, 2016.